3,4-Dihydro-2H-benzo [4, 5] isothiazolo [2,3-a] 
Introduction
A variety of anti-HIV drugs targeted to each stage of the infection have been developed for the treatment of human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS). 1 In particular, highly active antiretroviral therapy (HAART) by co-administration of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs) is a standard treatment regimen for HIV-infected patients. 2 The HAART regimen strongly suppresses viral proliferation and has provided significant decline of morbidity and mortality, 3 but a complete cure or eradication of HIV has not yet been achieved. Long-term administration of multiple antiretroviral agents causes the emergence of drug-resistant HIV variants and drug-related adverse effects, 4, 5 resulting in increased risk of virologic failure and/or limitation in the treatment strategy. 2 To overcome these problems, novel antiretroviral drugs with new mechanisms of action are now desired. Recently, a series of anti-HIV agents that inhibit an early stage of HIV infection are being explored, including the fusion inhibitor enfuvirtide, 6 a CC chemokine receptor type 5 (CCR5) antagonist (maraviroc), 7 CXC chemokine receptor type 4 (CXCR4) antagonists, 8, 9 and CD4 mimics. 10 Previously, we and others reported 3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (1, PD 404182) [11] [12] [13] [14] as a new antiviral agent against human hepatitis C virus (HCV), 15, 16 HIV, [16] [17] [18] [19] [20] simian immunodeficiency virus (SIV), 16 and herpes simplex virus (HSV) (Figure 1 ). 20 A structureactivity relationship (SAR) study on compound 1 suggested that the 6-imino group and 7-sulfur atom were essential to interact with the potential target molecule(s), which was supported by a complete loss of its anti-HIV activity by substitution of these groups with other heteroatoms. Optimization of the benzene ring and the cyclic amidine moieties in the pyrimido[1,2-c][1,3]benzothiazin-6-imine scaffold demonstrated that the introduction of hydrophobic aryl moieties such as m-anisyl and 3,4-methylenedioxyphenyl groups into the 9-position improved the anti-HIV activity three-fold. 17, 18 The antiviral profile of 1 indicated that the pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives inhibited early-stage HIV infection including virus attachment and membrane fusion to host cells as exemplified by DS 5000 (adsorption inhibitor) 21 and enfuvirtide (fusion inhibitor) 6 . Although it was suggested that compound 1 exerts its virucidal effect against viral particles, 16, 20 its antiviral mechanism of action has not yet been sufficiently detailed.
During the course of our investigations of PD 404182 derivatives, 3,4-dihydro-2H-benzo [4, 5] isothiazolo[2,3-a]pyrimidine 2 was found to exhibit potent anti-HIV activity (EC50 = 0.29 M) (Figure 1 ). The structure of this unprecedented scaffold was verified by X-ray crystal analysis.
Although there have been several reports that similar isothiazolidine and thiadiazole derivatives exhibited anti-HIV activities as zinc finger inhibitors for HIV-1 nucleocapsid protein 7 (NCp7), 22, 23 this tetrahydropyrimidine-fused heterocyclic scaffold has not been explored as a potential anti-HIV agent candidate. In the current study, we investigated the synthesis of benzo [4, 5] isothiazolo [2,3- a]pyrimidine derivatives and their structure-activity relationships as potent anti-HIV agents.
Results and Discussion

Synthesis of benzo[4,5]isothiazolo[2,3-a]pyrimidine derivatives
Our investigation began with the synthesis of benzo [4, 5] isothiazolo [2,3-a] pyrimidine scaffold 9 having a characteristic S-N covalent bond, formed by oxidation of 2-(tetrahydropyrimidin-2-yl)thiophenol derivative 8 (Scheme 1). Previously we reported the synthesis of PD 404182 derivative 6 with the pyrimido[1,2-c][1,3]benzothiazin-6-imine core. [17] [18] [19] 24 Briefly, the oxidative amidination 25 of various benzaldehydes 3 gave the corresponding 2-phenyltetrahydropyrimidine derivative 4. SNArtype C-S bond formation on 4 with tert-butyl isothiocyanate afforded N-(tert-butyl)-protected thiazinimine 5, which was subjected to deprotection of the tert-butyl group with trifluoroacetic acid (TFA) to provide PD 404182 derivative 6. The subsequent TFA-mediated ethanolysis of the imino group in 6c-i,k,l,n generated the thiophenol precursor 8. Without isolation of the thiophenol 8, the desired benzo [4, 5] isothiazolo [2,3-a] pyrimidines 9c-i,k,l,n were obtained after linking the thiol group and cyclic amidine NH group by phenyliodine diacetate (PIDA) 26 -mediated oxidation. Alternatively, pyrimido[1,2-c][1,3]benzothiazin-6-thione derivatives 7j,m were synthesized by addition of carbon disulfide to derivatives 4j,m followed by SNAr-type C-S bond formation. 24, 27 Alkaline hydrolysis of the thiocarbonyl group of 7j,m followed by PIDA-mediated oxidation gave the compounds 9j,m. The benzo [4, 5] isothiazolo[2,3-a]pyrimidine derivatives 9c-n were derivatized from benzothiazin-6-imine 6 and the precursor 7, 24 which were employed for our previous structure-activity relationship studies of PD 404182 derivatives. 17, 18 A series of 8-aryl benzo [4, 5] were consecutively removed. Ullmann coupling of bromide 5d with azoles followed by subsequent manipulations afforded pyrazole and triazole derivatives 14a,b.
Structure-activity relationship study of the anti-HIV activity of benzo[4,5]isothiazolo[2,3-
a]pyrimidine derivatives
Initially, we investigated the modifications of the benzo [4, 5] isothiazolo[2,3-a]pyrimidine derivatives at the 7-, 8-and 9-positions (Table 1) . The anti-HIV activity of a series of compounds was evaluated by the NCK assay, 28 in which the inhibition of virus attachment and membrane fusion to host cells during early-stage HIV infection is evaluated. The 8-phenyl modification (9a) maintained the potency of the lead compound 2 (EC50 = 0.30 M), while the m-anisyl (9b) and bromo (9d) derivative exhibited two to three times greater anti-HIV activity (EC50 (9b) = 0.10 M, EC50 (9d) = 0.22 M). In contrast, the methoxy (9c), trifluoromethyl (9e) and nitro (9f) groups slightly decreased the anti-HIV activity, and the 8-acetamide group in 9g remarkably attenuated the activity.
Modifications at the 9-position of benzo [4, 5] isothiazolo[2,3-a]pyrimidine were also unfavorable for anti-HIV activity. 9-Phenyl (9i), methyl (9j), methoxy (9k), bromo (9l) and trifluoromethyl (9m)-modified derivatives showed two-to seven-fold less anti-HIV activity compared with compound 2. On the basis of the initial structure-activity relationships of the benzo [4, 5] isothiazolo [2,3- a]pyrimidine derivatives, further modifications on the 8-aryl substituent were carried out (Table 2) .
First, we modified the para-and meta-positions of the 8-phenyl group in compound 9a. The methoxy (9o and 9b), methoxycarbonyl (9p and 9r) and nitro (9q and 9s) groups improved the anti-HIV activity (EC50 = 0.05-0.16 M), which was approximately two-to six-fold greater compared with compound 2. Because the effects by introduction of electron-withdrawing and electron-donating substituents on the aromatic ring were similar, the electron density of the 8-phenyl group is unlikely to be the primary factor for the interaction with the target molecule(s). Para-and meta-hydroxy groups (11a and 11b) reduced the anti-HIV activity (EC50 = 1.28 and 1.47 M, respectively). The substitution of the 8-phenyl group with a variety of hetero-and carbocyclic substructures was also investigated. The hydrophobic 3,4-methylenedioxyphenyl (9t), 2-naphthyl (9u), furan-2-yl (9v) and thiophen-3-yl (9w) groups increased the anti-HIV activity. In contrast, substitution with basic heterocycles such as pyridine (9x-z), pyrazole (14a) and triazole (14b) resulted in a slight decrease of the anti-HIV activity compared with compound 9a, suggesting that nitrogen heterocycles are not favorable at this position.
These results indicated that favorable hydrophobic interaction(s) of the 8-aryl groups with the potential target molecule(s) could play important roles for determining the anti-HIV activity.
Cytotoxic effects were not observed at 10 M except for compound 9o.
Mechanistic studies of anti-HIV isothiazolopyrimidine derivatives
We executed a time of drug addition study to estimate the mechanism of action of the isothiazolopyrimidine derivatives (Figure 2) . In our previous studies, we determined that PD 404182
(1) and its derivatives inhibited an early stage of HIV infection. 17, 18 In this study, compound 2 and potent derivatives 9r and 9v were evaluated for their anti-HIV activity profiles compared with anti-HIV agents including DS 5000 (adsorption inhibitor), 21 enfuvirtide (fusion inhibitor), 6 AZT (NRTI), 29 nevirapine (NNRTI), 30 and raltegravir (integrase inhibitor). 31 Isothiazolopyrimidine derivatives 2, 9r, and 9v had similar inhibitory profiles to that of DS 5000 and compound 1, which prevent an early stage of viral infection including the attachment and entry into the target cells. It should also be noted that both compounds 1 and 2 showed a broad spectrum of antiviral activity against RNA viruses and DNA viruses (data not shown). These results may suggest that these two series of compounds may have an identical or similar target molecule(s) or mechanism of action for the antiviral activities.
Although a possible common viral target molecule(s)
has not yet been identified, 32 these derivatives could positively regulate the defense mechanism(s) of the host cells.
Conclusions
In this study, we identified a novel class of small-molecule anti-HIV agents with the benzo [4, 5] 
Anti-HIV activity
The anti-HIV activity of a series of compounds against HIV-1IIIB was determined by the NCK assay. 
